Literature DB >> 18057571

Workplace discrimination and cancer.

Maureen A McKenna1, Ellen Fabian, Jessica E Hurley, Brian T McMahon, Steven L West.   

Abstract

Data from the Equal Employment Opportunity Commission (EEOC) Integrated Mission System database were analyzed with specific reference to allegations of workplace discrimination filed by individuals with cancer under ADA Title One. These 6,832 allegations, filed between July 27, 1992 and September 30, 2003, were compared to 167,798 allegations from a general disability population on the following dimensions: type of workplace discrimination; demographic characteristics of the charging parties (CPs); the industry designation, location, and size of employers; and the outcome or resolution of EEOC investigations. Results showed allegations derived from CPs with cancer were more likely than those in the general disability population to include issues involving discharge, terms and conditions of employment, lay-off, wages, and demotion. Compared to the general disability group, CPs with cancer were more likely to be female, older, and White. Allegations derived from CPs with cancer were also more likely to be filed against smaller employers (15-100 workers) or those in service industries. Finally, the resolution of allegations by CPs with cancer were more likely to be meritorious than those filed from the general disability population; that is, actual discrimination is more likely to have occurred.

Entities:  

Mesh:

Year:  2007        PMID: 18057571

Source DB:  PubMed          Journal:  Work        ISSN: 1051-9815


  2 in total

1.  The Workplace Discrimination Experiences of Individuals with Cancer in the Americans with Disabilities Act Amendments Act Era.

Authors:  Mykal Leslie; David R Strauser; Brian McMahon; Chelsea Greco; Phillip D Rumrill
Journal:  J Occup Rehabil       Date:  2020-03

Review 2.  Work in cancer survivors: a model for practice and research.

Authors:  Michael Feuerstein; Briana L Todd; Michal C Moskowitz; Gina L Bruns; Mallori R Stoler; Thomas Nassif; Xinhua Yu
Journal:  J Cancer Surviv       Date:  2010-10-14       Impact factor: 4.442

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.